Theophylline glycinate
As of the edition of 20 October 2026, Theophylline glycinate is a small molecule: marketed, first approved in 1982 (US); acts on ADORA1, ADORA2A and ADORA2B and 7 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Synophylate
- First approved
- 1 January 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Central Pharmaceuticals
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ADORA3 | Adenosine receptor A3 | P0DMS8 |
| PDE4A | 3',5'-cyclic-AMP phosphodiesterase 4A | P27815 |
| ADORA2A | Adenosine receptor A2a | P29274 |
| ADORA2B | Adenosine receptor A2b | P29275 |
| ADORA1 | Adenosine receptor A1 | P30542 |
| PDE4B | 3',5'-cyclic-AMP phosphodiesterase 4B | Q07343 |
| PDE4C | 3',5'-cyclic-AMP phosphodiesterase 4C | Q08493 |
| PDE4D | 3',5'-cyclic-AMP phosphodiesterase 4D | Q08499 |
| PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B | Q13370 |
| PDE3A | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A | Q14432 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Central Pharmaceuticals | Acquired holder | 2003 to now |